{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-033797","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.873498+00:00","generated_at":"2026-05-23T17:25:16.421743+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gain Therapeutics Announces Additional Preclinical Data and Phase 1b Study Design for GT-02287 in Parkinson's Disease","bullets":["GT-02287 showed disease-modifying potential in GBA1 and idiopathic Parkinson's disease models, with biomarkers statistically reduced and lasting after drug washout.","Phase 1b study ongoing; early biomarker analysis of enrolled participants expected mid-2025, including GBA1 mutation carriers and non-carriers.","Complete Phase 1b endpoint analysis after 90 days of treatment anticipated in Q4 2025, guiding Phase 2 design in H2 2025.","Oral presentation at AD/PD 2025 highlighted behavioral and biomarker data supporting GT-02287's disease-modifying capacity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-033797","json":"https://secwatch.observer/filing/0001104659-25-033797.json","markdown":"https://secwatch.observer/filing/0001104659-25-033797.md","text":"https://secwatch.observer/filing/0001104659-25-033797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925033797/0001104659-25-033797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925033797/tm2512000d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-23T17:25:16.421743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}